Valuation: Compugen Ltd.

Market Cap 188M 168M 155M 140M 262M 17.81B 267M 1.84B 740M 9.37B 704M 689M 29.54B P/E 2026 *
-7.07x
P/E 2027 * -7.17x
Enterprise Value 188M 168M 155M 140M 262M 17.81B 267M 1.84B 740M 9.37B 704M 689M 29.54B EV / Sales 2026 *
20.3x
EV / Sales 2027 * 24.2x
Free-Float
99.61%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Compugen Ltd.

1 day-2.94%
1 week+2.06%
Current month-16.81%
1 month-16.81%
3 months-15.20%
6 months-25.56%
Current year+29.41%
1 week 1.87
Extreme 1.87
2.07
1 month 1.87
Extreme 1.87
2.38
Current year 1.51
Extreme 1.51
3.24
1 year 1.43
Extreme 1.43
3.24
3 years 0.53
Extreme 0.53
3.24
5 years 0.51
Extreme 0.51
7.48
10 years 0.51
Extreme 0.51
19.9
Manager TitleAgeSince
Chief Executive Officer - 23/09/2025
Director of Finance/CFO 42 15/08/2024
Chief Operating Officer 49 01/01/2024
Director TitleAgeSince
Chairman 59 23/09/2025
Director/Board Member 59 11/06/2018
Director/Board Member 70 11/06/2018
Date Insider Type Main position Quantity % Market Cap. Importance
29/7/26 Free

Chief Operating Officer

70,000 0.0740%
29/7/26 Free

Chairman

100,000 0.1058%
29/7/26 Free

Chief Financial Officer

45,500 0.0481%
Change 5-day change 1-year change 3-year change Capi.($)
-2.94%+2.06%+20.00%+189.05% 188M
-0.62%-1.87%+46.31%+56.99% 63.77B
+0.35%+3.20%+14.92%+84.55% 56.37B
+0.53%+1.96%+15.37%+106.81% 54.62B
-2.81%-4.31%+23.50%+50.90% 44.06B
-0.33%-1.93%+20.15%+98.45% 42.11B
+0.55%+2.31%+224.97%+942.56% 41B
+3.27%+47.96%+112.67%+96.48% 34.92B
+1.22%-1.44%+14.89%+47.15% 32.82B
+0.89%+20.55%-42.03%+373.03% 24.7B
Average +0.01%+6.99%+45.07%+204.60% 39.45B
Weighted average by Cap. +0.18%+5.44%+48.49%+186.13%

Financials

2026 *2027 *
Net sales 9.24M 8.27M 7.61M 6.9M 12.89M 877M 13.13M 90.76M 36.44M 461M 34.67M 33.94M 1.46B 7.75M 6.94M 6.38M 5.78M 10.81M 736M 11.02M 76.14M 30.56M 387M 29.08M 28.47M 1.22B
Net income -26.46M -23.7M -21.8M -19.75M -36.93M -2.51B -37.62M -260M -104M -1.32B -99.32M -97.21M -4.17B -26.95M -24.14M -22.2M -20.12M -37.6M -2.56B -38.31M -265M -106M -1.35B -101M -98.99M -4.25B
Net Debt - -
Projected Income Statement - Annual - Compugen Ltd.
Logo Compugen Ltd.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Employees
75
Date Price Change Volume
30/10/26 US$1.980 -2.94% 255,458
29/10/26 US$2.040 +1.49% 142,900
28/10/26 US$2.010 +2.03% 149,268
27/10/26 US$1.970 +5.07% 131,408
26/10/26 US$1.875 -3.35% 334,469
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Compugen Ltd.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.980USD
Average target price
4.600USD
Spread / Average Target
+132.32%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Compugen Ltd.
  1. Stock Market
  2. Stocks
  3. CGEN Stock